Agency: Cordis | Branch: FP7 | Program: CSA-CA | Phase: REGIONS | Award Amount: 2.41M | Year: 2010
Challenge: Health-TIES addresses Europes largest health challenges: an ageing population and the sustainability of the healthcare system. This cross-border challenge needs a collaborative approach! Third revolution: True collaboration between medical scientists, engineers, healthcare providers, industry and government is the key to innovation in healthcare (the third revolution). Health-TIES is at the forefront: a transnational consortium in medical technology comprising four top regions in biosciences, technology and entrepreneurship: Biocat (Catalonia), Medical Delta (West Netherlands), Oxford/Thames Valley, Canton de Zurich and a mentoring region szak-Alfld (Hungary). Common goals: To maximise the impact of innovation and RTD on healthcare, Health-TIES will stimulate joint science, education and state-of-the-art infrastructure; and boost the Healthcare Technology Innovation Cycle. S&T meet patients: Breakthroughs in molecular technology, imaging, and drug design have created new avenues for prevention (risk factor identification, early diagnosis) and more effective treatment. Health-TIES will apply these to Cardiovascular diseases, Cancer, Neurodegenerative diseases, Immunology & Infectious diseases. Accelerate innovation: Health-TIES will accelerate the Healthcare Technology Innovation Cycle, which connects engineers and medical professionals, scientists and entrepreneurs, developers and end-users. Policy makers will be engaged in developing the RTD agenda. Analyse, integrate, disseminate: Health-TIES activities include: analysing innovation performance; attracting SMEs; exchanging staff and students; entrepreneurial training; connecting stakeholders; involving end-users in RTD; sharing best-practices through a Virtual Reference Region and ICT-tools. Better health(care): Health-TIES will contribute to improved health of EU citizens, better-equipped medical doctors, more efficient and effective healthcare systems, and an economically viable sector.
Neurotune AG | Date: 2011-03-16
Modified agrin fragment having in vivo activity, comprising at least the domains LG2 and LG3 of human agrin in covalently interlinked form and modified in such a way that the fragment cannot be cleaved by neurotrypsin for use as medicament.
Neurotune AG | Date: 2012-08-08
A method for the production of a hybridoma cell lines producing monoclonal antibodies capable to specifically binding to a human C44-fragment of agrin, comprising administering to wild-type-mice an immunizing amount of C44y4-fragment of agrin, isolating antibody producing cells from the immunized mice, fusing them with a myeloma cell line, growing the fused cells in a selection medium, screening the antibodies in the supernatants of hybridoma cells for binding to C44-fragment of agrin and isolating the hybridoma cells producing the desired monoclonal antibodies
Neurotune AG | Date: 2013-07-31
The use of dimiracetam in the treatment of chronic pain chronic pain induced by osteoarthritis, rheumatoid arthritis or autoimmune osteoarthrosis forms is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.
Neurotune Ag | Date: 2013-02-22
Method for the determination of the renal function wherein the amount of at least one agrin fragment derived by neurotrypsin cleavage of agrin is measured in a sample taken from a patient and the measured amount of the agrin-fragment in the sample is used as indicator for renal function.
Neurotune Ag | Date: 2011-07-25
The invention relates to a method of manufacture of dimiracetam (2,5-dioxohexahydro-1 H-pyrrolo[1,2-a]imidazole), characterized in that a 4-oxo-butanoic acid ester is condensed with glycinamide in a one-pot reaction with a controlled pH. The reaction may be performed in aqueous solution or in an anhydrous lower alcohol solution.
Neurotune AG | Date: 2016-08-03
Modified agrin fragment having in vivo activity, comprising at least the domains LG2 and LG3 of human or mouse agrin in covalently interlinked form and modified in such a way that the fragment cannot be cleaved by neurotrypsin for use in the treatment of neuromuscular diseases or diseases of nerve, muscle and neuromuscular junctions, wherein the modified agrin fragment is characterized in that its -cleavage site is deleted or modified.
Neurotune Ag | Date: 2011-10-25
Dimiracetam is a suitable drug for treating and preventing allodynia, in particular allodynia of the hands and feet, that is or may be induced by antitumoral chemotherapeutic treatment with sorafenib.
Neurotune AG | Date: 2015-04-08
The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose.
Neurotune AG | Date: 2013-08-28
Immunoassay for the detection of CAF (22-Kd fragment of agrin) in a sample, which additionally can include larger agrin-fragments (110-Kd fragment) and agrin itself and in which the CAF to be detected can be present in one or both of the following 2 different conformations CAF-closed and CAF-open, wherein in an optional first step the larger fragments and agrin possibly present in the sample are removed therefrom, in a second step the remaining portion of the sample obtained after possible removal of the larger fragments in the first step is incubated with a (primary) antibody with known binding properties to the different conformations of the CAF, with the antibody being capable to specifically bind to at least the CAF-open conformation, and in a third step it is determined whether or not antibody-CAF-complexes have been formed after incubation.